LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 5 of 497
Next
>>
>
101 to 125 of 12420 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	CGP60474	0.04	uM	LJP6	2	G06	72	hr	1097	781	3769	0.2072	-0.1184
BT-20	CGP60474	0.04	uM	LJP6	3	G06	72	hr	1097	712	3769	0.1889	-0.1442
BT-20	CHIR-99021	0.04	uM	LJP6	1	P18	72	hr	1097	2953	3769	0.7834	0.6944
BT-20	CHIR-99021	0.04	uM	LJP6	2	P18	72	hr	1097	3323	3769	0.8815	0.8329
BT-20	CHIR-99021	0.04	uM	LJP6	3	P18	72	hr	1097	3301	3769	0.8757	0.8247
BT-20	CP724714	0.04	uM	LJP5	1	A12	72	hr	1097	3642	3769	0.9662	0.9523
BT-20	CP724714	0.04	uM	LJP5	2	A12	72	hr	1097	3518	3769	0.9333	0.9059
BT-20	CP724714	0.04	uM	LJP5	3	A12	72	hr	1097	3746	3769	0.9938	0.9912
BT-20	CP466722	0.04	uM	LJP5	1	I12	72	hr	1097	4205	3769	1.1155	1.1630
BT-20	CP466722	0.04	uM	LJP5	2	I12	72	hr	1097	4118	3769	1.0924	1.1304
BT-20	CP466722	0.04	uM	LJP5	3	I12	72	hr	1097	4015	3769	1.0651	1.0919
BT-20	Crizotinib	0.04	uM	LJP5	1	A24	72	hr	1097	3169	3769	0.8407	0.7753
BT-20	Crizotinib	0.04	uM	LJP5	2	A24	72	hr	1097	3345	3769	0.8874	0.8411
BT-20	Crizotinib	0.04	uM	LJP5	3	A24	72	hr	1097	3506	3769	0.9301	0.9014
BT-20	Momelotinib	0.04	uM	LJP5	1	P12	72	hr	1097	3291	3769	0.8731	0.8209
BT-20	Momelotinib	0.04	uM	LJP5	2	P12	72	hr	1097	3966	3769	1.0521	1.0735
BT-20	Momelotinib	0.04	uM	LJP5	3	P12	72	hr	1097	3721	3769	0.9871	0.9818
BT-20	Dasatinib	0.04	uM	LJP5	1	D06	72	hr	1097	3074	3769	0.8155	0.7397
BT-20	Dasatinib	0.04	uM	LJP5	2	D06	72	hr	1097	3202	3769	0.8494	0.7876
BT-20	Dasatinib	0.04	uM	LJP5	3	D06	72	hr	1097	2951	3769	0.7829	0.6937
BT-20	Dasatinib	0.04	uM	LJP6	1	I06	72	hr	1097	1559	3769	0.4136	0.1728
BT-20	Dasatinib	0.04	uM	LJP6	2	I06	72	hr	1097	1550	3769	0.4112	0.1694
BT-20	Dasatinib	0.04	uM	LJP6	3	I06	72	hr	1097	1704	3769	0.4520	0.2271
BT-20	Dovitinib	0.04	uM	LJP5	1	E24	72	hr	1097	3454	3769	0.9163	0.8819
BT-20	Dovitinib	0.04	uM	LJP5	2	E24	72	hr	1097	3307	3769	0.8773	0.8269

|<
<<
Previous
Page 5 of 497
Next
>>
>
101 to 125 of 12420 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 3 of 15: Cell count and relative growth within biological replicate 3. - Dataset (ID:20239)